ProTransit Nanotherapy Inc. is a debt-free, Omaha, NE-based, drug delivery platform company that is primarily focused on the topical delivery of APIs to the skin. Our unique, patented, and sustained-release nanoparticles (Pro-NP™) can encapsulate a wide range of APIs and provide increased skin penetration, protection of actives, and up to 90 hours of sustained release at the application site. We make drugs safer, faster, and better than other forms of delivery and can provide new patent life to existing or new compounds. ProTransit has completed pilot clinical trials on sun damage, hair regrowth, and plaque psoriasis. Immediate (2023), near-term (2024), and long-term commercialization plans are underway.
UV sun damage: The company received NIH grants supporting studies on the reduction/prevention of skin damage, photoaging, and skin cancer caused by UV-induced free radicals. Pro-NP has encapsulated and patented the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) and demonstrated a near complete quenching of free radicals formed by UV light exposure--significantly better than sunscreens alone. In clinical trials, the appearance of sun-damaged skin improved following 3 months of daily application of Pro-NP SOD-CAT. Biopsies of the sun-damaged patients showed up to a doubling of the skin’s dermis and extensive tissue repair. ProTransit will launch market-disruptive, next-generation sunscreens in Q3 ’23 - Q1 ‘24 with nationwide distribution in collaboration with an established partner in the sun care space. Unlike current sunscreens, the products will provide unprecedented 24-7 protection from free radicals and feature OTC drug facts structure-function labeling under the FDA sunscreen monograph.
Hair regrowth: Clinical trial results using Pro-NP finasteride for only 3 months surpassed industry benchmarks set by 1-year use of minoxidil and finasteride. Near-term commercialization (Q1 ’24) will use a web-based telemedicine platform to promote and sell an Rx compounded product.
Plaque psoriasis: a pilot clinical trial using Pro-NP topical cyclosporine was encouraging. This product will follow the FDA NDA long-term pathway to commercialization.
The Series A round of $20M was launched in January ’23 at Bio Investor/ CEO Forum in NYC. Other funding will come from a combination of dilutive and non-dilutive sources (grants, product sales, and company collaborations). SAFEs (bridge funding) of $50-150K each are still available for high-net-worth investors.
Funds will be used for additional clinical trials, scale-up, marketing, and advertising of immediate and near-term products.
Ready to Ask For Funding for your company?
Post a Funding Request